586 related articles for article (PubMed ID: 29577277)
1. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
[TBL] [Abstract][Full Text] [Related]
2. DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma.
Weygant N; Qu D; May R; Tierney RM; Berry WL; Zhao L; Agarwal S; Chandrakesan P; Chinthalapally HR; Murphy NT; Li JD; Sureban SM; Schlosser MJ; Tomasek JJ; Houchen CW
Oncotarget; 2015 Feb; 6(4):2193-205. PubMed ID: 25605241
[TBL] [Abstract][Full Text] [Related]
3. Doublecortin-Like Kinase 1 (DCLK1) Regulates B Cell-Specific Moloney Murine Leukemia Virus Insertion Site 1 (Bmi-1) and is Associated with Metastasis and Prognosis in Pancreatic Cancer.
Li J; Wang Y; Ge J; Li W; Yin L; Zhao Z; Liu S; Qin H; Yang J; Wang L; Ni B; Liu Y; Wang H
Cell Physiol Biochem; 2018; 51(1):262-277. PubMed ID: 30453285
[TBL] [Abstract][Full Text] [Related]
4. Curcumin promotes autophagic survival of a subset of colon cancer stem cells, which are ablated by DCLK1-siRNA.
Kantara C; O'Connell M; Sarkar S; Moya S; Ullrich R; Singh P
Cancer Res; 2014 May; 74(9):2487-98. PubMed ID: 24626093
[TBL] [Abstract][Full Text] [Related]
5. Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells.
Chandrakesan P; Yao J; Qu D; May R; Weygant N; Ge Y; Ali N; Sureban SM; Gude M; Vega K; Bannerman-Menson E; Xia L; Bronze M; An G; Houchen CW
Mol Cancer; 2017 Feb; 16(1):30. PubMed ID: 28148261
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of LEF1-Mediated DCLK1 by Niclosamide Attenuates Colorectal Cancer Stemness.
Park SY; Kim JY; Choi JH; Kim JH; Lee CJ; Singh P; Sarkar S; Baek JH; Nam JS
Clin Cancer Res; 2019 Feb; 25(4):1415-1429. PubMed ID: 30446587
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1.
Ikezono Y; Koga H; Akiba J; Abe M; Yoshida T; Wada F; Nakamura T; Iwamoto H; Masuda A; Sakaue T; Yano H; Tsuruta O; Torimura T
Mol Cancer Res; 2017 Jun; 15(6):744-752. PubMed ID: 28179411
[TBL] [Abstract][Full Text] [Related]
8. CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis.
Gassenmaier M; Chen D; Buchner A; Henkel L; Schiemann M; Mack B; Schendel DJ; Zimmermann W; Pohla H
Stem Cells; 2013 Aug; 31(8):1467-76. PubMed ID: 23630186
[TBL] [Abstract][Full Text] [Related]
9. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
[TBL] [Abstract][Full Text] [Related]
10. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1.
Weygant N; Qu D; Berry WL; May R; Chandrakesan P; Owen DB; Sureban SM; Ali N; Janknecht R; Houchen CW
Mol Cancer; 2014 May; 13():103. PubMed ID: 24885928
[TBL] [Abstract][Full Text] [Related]
11. BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation.
Wang L; Park P; La Marca F; Than KD; Lin CY
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1013-24. PubMed ID: 25431339
[TBL] [Abstract][Full Text] [Related]
12. Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism.
Sureban SM; Madhoun MF; May R; Qu D; Ali N; Fazili J; Weygant N; Chandrakesan P; Ding K; Lightfoot SA; Houchen CW
Oncotarget; 2015 Nov; 6(35):37200-15. PubMed ID: 26468984
[TBL] [Abstract][Full Text] [Related]
13. PIN1 Inhibition Sensitizes Chemotherapy in Gastric Cancer Cells by Targeting Stem Cell-like Traits and Multiple Biomarkers.
Zhang ZZ; Yu WX; Zheng M; Liao XH; Wang JC; Yang DY; Lu WX; Wang L; Zhang S; Liu HK; Zhou XZ; Lu KP
Mol Cancer Ther; 2020 Mar; 19(3):906-919. PubMed ID: 31879364
[TBL] [Abstract][Full Text] [Related]
14. Differentiation therapy: targeting human renal cancer stem cells with interleukin 15.
Azzi S; Bruno S; Giron-Michel J; Clay D; Devocelle A; Croce M; Ferrini S; Chouaib S; Vazquez A; Charpentier B; Camussi G; Azzarone B; Eid P
J Natl Cancer Inst; 2011 Dec; 103(24):1884-98. PubMed ID: 22043039
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.
Muñoz-Galván S; Felipe-Abrio B; Verdugo-Sivianes EM; Perez M; Jiménez-García MP; Suarez-Martinez E; Estevez-Garcia P; Carnero A
Mol Cancer; 2020 Jan; 19(1):7. PubMed ID: 31926547
[TBL] [Abstract][Full Text] [Related]
16. Immune Cell Production of Interleukin 17 Induces Stem Cell Features of Pancreatic Intraepithelial Neoplasia Cells.
Zhang Y; Zoltan M; Riquelme E; Xu H; Sahin I; Castro-Pando S; Montiel MF; Chang K; Jiang Z; Ling J; Gupta S; Horne W; Pruski M; Wang H; Sun SC; Lozano G; Chiao P; Maitra A; Leach SD; Kolls JK; Vilar E; Wang TC; Bailey JM; McAllister F
Gastroenterology; 2018 Jul; 155(1):210-223.e3. PubMed ID: 29604293
[TBL] [Abstract][Full Text] [Related]
17. DCLK1 integrates induction of TRIB3, EMT, drug resistance and poor prognosis in colorectal cancer.
Makino S; Takahashi H; Okuzaki D; Miyoshi N; Haraguchi N; Hata T; Matsuda C; Yamamoto H; Mizushima T; Mori M; Doki Y
Carcinogenesis; 2020 May; 41(3):303-312. PubMed ID: 31562741
[TBL] [Abstract][Full Text] [Related]
18. DCLK1 inhibition attenuates tumorigenesis and improves chemosensitivity in esophageal squamous cell carcinoma by inhibiting β-catenin/c-Myc signaling.
Zhang L; Zhou S; Guo E; Chen X; Yang J; Li X
Pflugers Arch; 2020 Aug; 472(8):1041-1049. PubMed ID: 32533239
[TBL] [Abstract][Full Text] [Related]
19. Notch signaling plays a crucial role in cancer stem-like cells maintaining stemness and mediating chemotaxis in renal cell carcinoma.
Xiao W; Gao Z; Duan Y; Yuan W; Ke Y
J Exp Clin Cancer Res; 2017 Mar; 36(1):41. PubMed ID: 28279221
[TBL] [Abstract][Full Text] [Related]
20. Role of doublecortin-like kinase 1 and leucine-rich repeat-containing G-protein-coupled receptor 5 in patients with stage II/III colorectal cancer: Cancer progression and prognosis.
Kang XL; He LR; Chen YL; Wang SB
World J Gastroenterol; 2020 Nov; 26(43):6853-6866. PubMed ID: 33268966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
